---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115533"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:58:46.943596+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028

## Summary
- Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.
- Net loss $28.5M ($0.20/ADS) vs $2.3M ($0.02) in Q1 2024; R&D up $9.0M to $20.8M.
- Divesiran Phase 2 SANRECO enrollment on track to complete by year-end 2025; EHA presentation June 12-15.
- Cost savings initiatives implemented to extend cash guidance into 2028; Phase 3 readiness for zerlasiran ongoing.
- Appointed Tim McInerney to Board of Directors effective May 5, 2025.

## SEC filing metadata
- accession: 0001193125-25-115533
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/0001193125-25-115533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/d932196d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115533
- JSON: https://secwatch.observer/filing/0001193125-25-115533.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.